From growth companies to multinationals and leading institutions, we offer a wealth of expertise in corporate transactions to a diverse and innovative client base. Our advice is clear, pragmatic and, crucially, aligned with the client’s strategic goals.

Our experienced lawyers advise on every aspect of corporate transactions and leverage the firm’s full-service offering to provide business-critical advice in key areas such as tax, employment, UK and EU competition/anti-trust, regulatory, real estate, IT, data protection and IP issues.

Our market-leading strengths in IP and technology mean we are uniquely well-placed to counsel clients in dynamic sectors such as technology, life sciences and brands. We draw on our understanding of these sectors to advise corporate and institutional clients acquiring or evaluating IP and technology portfolios, helping them to secure commercially-relevant legal protections and to acquire, sell or invest with confidence.

We carry out both domestic and cross-border transactional work advising on private and public mergers & acquisitions, disposals, spin-outs, and corporate reorganisations. We also have considerable experience of advising on domestic and international joint ventures, helping our clients expand and develop their business into new areas and new markets.

With regard to finance transactions, we act for businesses raising finance as well as for the finance providers including venture capital firms, private equity firms and corporate venturing houses. We are recognised for our market leading expertise advising technology and life sciences growth companies at all stages of the evolutionary cycle of equity financing transactions including early stage financings, Series A and Series B, growth equity and pre-IPO cross-over finance. We also advise numerous equity providers in these sectors on their investments from Series A onwards and act for many of the world’s leading companies on their corporate venturing programmes.

Our debt experience includes advising on corporate borrowing and secured lending transactions, acquisition finance and debt refinance as well as venture debt and convertible equity instruments.

We also offer the full range of services for equity capital market (ECM) transactions and have experience in handling primary and secondary offerings on both the UK markets and NASDAQ from a UK perspective.

On cross-border transactions, we draw on a network of specialist lawyers from independent law firms around the world in order to provide a seamless service. A key differentiator of Bristows’ network as compared with that of “global brand” firms is our ability to choose the best firms for any particular transaction rather than being tied to one firm or office in each jurisdiction.

Key contact

Iain Redford

Contact

Experience

We advised epigenetics company Base Genomics on its $11 million USD seed financing to commercialise their technology for early and sensitive detection of cancer from liquid biopsy.

DeepMatter Group plc on the sale of the lonscope business, its acquisition of InfoChem from Springer Nature, placing and Rule 9 Takeover Code waiver.

Hedge fund Tybourne Capital Management on its Series B investments into Bicycle Therapeutics limited, a clinical stage biotechnology company.

IP Group plc on the transfer back to Imperial College of the technology transfer office of the university.

Janssen on its participation in the establishment of the UK's first dedicated Vaccines Manufacturing Innovation Centre, as part of a consortium of academic and industry partners.

Syncona as lead investor in the Series A financing of OMass Therapeutics, a spin-out from Oxford University.

Capgemini on the acquisition of Adaptive Labs.

OneTrust, the global leader in privacy management and marketing compliance software, on its acquisitions of Governor Technology and DataGuidance.

Accel-KKR on its growth equity investment in global managed payroll and GEO SaaS business Safeguard Global.

Boeing HorizonX Ventures, the corporate venturing arm of Boeing, on its UK investments - including its investment into Reaction Engines.

AI-powered search marketing intelligence company Adthena on its Series A funding from Updata Partners.

Latest articles

What others say

“Others have claimed to have deep understanding in tech, but Bristows seem to walk the walk where others have not.”

Legal 500 2022

“Knowledgeable, pragmatic, provides sensible advice, and consequently value for money.”

Legal 500 2022

“They took the time to understand our business and risk appetite and this was factored in to the advice throughout.”

Legal 500 2022

“The [Fintech] team is ‘approachable, highly experienced and commercial in its advice’.”

Legal 500 2022

“Partners are very hands-on, always available and a pleasure to work with.”

Legal 500 2022

“The quality that Bristows provides is exceptionally high.”

Legal 500 2022

“They have a perfect understanding of the client’s needs and a diverse team of experts to fulfil these.”

Legal 500 2022

“Apart from their outstanding professional skills, all team members are very approachable and always open for a quick discussion.”

Legal 500 2022

“Exceptionally high quality life sciences practice.”

Legal 500 2022

“Full involvement and very well coordinated team advising us on different legal areas.”

Legal 500 2022

“Strong tech practice which is valuable for M&A in the tech sector.”

Legal 500 2022

“A ‘talented and pragmatic’ corporate team.”

Legal 500 2022

“Flexible team that is able to respond at short notice.”

Legal 500 2022

“I have tried other firms but Bristows are the most responsive and understand what we do best.”

Legal 500 2022

“They take time to invest in relationships.”

Legal 500 2022

Recent rankings and awards

Life Sciences: Transactional - Band 2

Fintech - Tier 3

M&A: (smaller deals up to £50m) - Tier 1